Comparison of Postoperative Analgesic Effect of Intrathecal Clonidine and Fentanyl Added to Bupivacaine in Patients Undergoing Cesarean Section
1 other identifier
interventional
90
1 country
1
Brief Summary
Objective :To compare the analgesic effect of intrathecal clonidine and fentanyl as an additive to bupivacaine in patients undergoing cesarean section . Methods:Following Ethics Committee approval and informed patients consent, Ninety patients 18-45 yr old ASA physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The clonidine group (groupC) received bupivacaine 10mg combined with 75microgram clonidine preservative free ,the fentanyl group (group F) received bupivacaine 10mg combined with25microgram fentanyl and the placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . Time to first requirement of analgesic supplement, Sensory block onset time, maximum sensory level , onset of motor block, duration of blockade, hemodynamics variables, the incidence of hypotension, ephedrine requirements, bradycardia ,hypoxemia \[Saturation of peripheral oxygen (SpO2)\<90\], postoperative analgesic requirements and Adverse events, such as sedation, dizziness , Pruritus and postoperative nausea and vomiting were recorded. Patients were instructed preoperatively in the use of the verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain) for pain assessment. If the VRS exceeded four and the patient requested a supplement analgesic, diclofenac Na supp 100 mg was to be given for post-operative pain relief as needed . For breakthrough pain(VRS \>4) if time of administration of diclofenac Na less than 8h,Pethidine 25 mg IV was given.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Aug 2011
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 28, 2011
CompletedFirst Posted
Study publicly available on registry
August 30, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2012
CompletedMay 17, 2012
May 1, 2012
5 months
August 28, 2011
May 16, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Time to first requirement of analgesic supplement
analgesic administration was initiated by patient request(verbal rating scale\[ VRS\]\>4)
participants will be followed for the duration of 24 hours after intratechal injection (Time from the injection of intrathecal anesthetic solution to first requirement of analgesic supplement will be recorded.
Postoperative analgesic requirements
postoperative analgesic requirements will be assessed by verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain).Each administration was initiated by patient request( VRS\>4)
24 hours postoperative(Time from the injection of intrathecal anesthetic solution to 24 hours postoperative)
Secondary Outcomes (4)
Sensory block onset time will be assessed by a pinprick test
sensory block will be assessed by pinprick test every 10 seconds following intrathecal injection
duration of sensory block will be assessed by a pinprick test
sensory block will be assessed by pinprick test every 5 minuts following intrathecal injection
the onset of motor block will be assessed by the modified Bromage score
every10 seconds following intrathecal injection
duration of motor block will be assessed by the modified Bromage score
every 5 minutes following intrathecal injection
Study Arms (3)
clonidine
ACTIVE COMPARATORThe clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
Fentanyl
ACTIVE COMPARATORThe fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
distilled water
PLACEBO COMPARATORThe placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
Interventions
The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
Eligibility Criteria
You may qualify if:
- Patients with American Society of Anesthesiologists(ASA) physical status I and II, undergoing elective cesarean section
You may not qualify if:
- Significant coexisting disease such as hepato-renal and cardiovascular disease
- Any contraindication to regional anesthesia such as local infection or bleeding disorders
- Allergy to ketamine or midazolam
- Long-term opioid use or a history of chronic pain. -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Qazvin university of medical science
Qazvin, Qazvin Province, 34197/59811, Iran
Related Publications (1)
Khezri MB, Rezaei M, Delkhosh Reihany M, Haji Seid Javadi E. Comparison of postoperative analgesic effect of intrathecal clonidine and fentanyl added to bupivacaine in patients undergoing cesarean section: a prospective randomized double-blind study. Pain Res Treat. 2014;2014:513628. doi: 10.1155/2014/513628. Epub 2014 Feb 4.
PMID: 24649361DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
August 28, 2011
First Posted
August 30, 2011
Study Start
August 1, 2011
Primary Completion
January 1, 2012
Study Completion
February 1, 2012
Last Updated
May 17, 2012
Record last verified: 2012-05